López, Mercedes N <br/><br/>
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2009 
 - 945-52 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.18.0794  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Cancer Vaccines--immunology<br/>Dendritic Cells--immunology<br/>Disease Progression<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Hypersensitivity, Delayed--immunology<br/>Male<br/>Melanoma--immunology<br/>Middle Aged<br/>Skin Neoplasms--immunology<br/>Survival Analysis<br/>T-Lymphocytes, Regulatory--immunology<br/>Transforming Growth Factor beta--biosynthesis